Manhattan Pharmaceuticals, Inc. (MHA) Provides Corporate Update on Hedrin and Management Restructuring, CEO Steps Down
6/18/2009 7:22:11 AM
More...
|
Manhattan Pharmaceuticals, Inc. (MHA) Completes $1 Million Financing
11/25/2008 8:43:20 AM
More...
|
Manhattan Pharmaceuticals, Inc. (MHA) Announces Results of Phase 2a Study of Topical PTH (1-34) for the Treatment of Psoriasis
8/1/2008 9:00:54 AM
More...
|
Manhattan Pharmaceuticals, Inc. (MHA) Announces Amendment of Joint Venture Deal With Nordic Biotech
6/13/2008 7:00:26 AM
More...
|
Manhattan Pharmaceuticals, Inc. (MHA) to Present At Rodman & Renshaw 5th Annual Global Healthcare Conference
5/19/2008 10:30:05 AM
More...
|
Manhattan Pharmaceuticals, Inc. (MHA) Announces Completion of Enrollment in Phase 2a Study of Topical PTH (1-34) for Psoriasis
4/10/2008 10:02:28 AM
More...
|
Manhattan Pharmaceuticals, Inc. (MHA) to Trade on OTCBB Under New Ticker Symbol MHAN
3/26/2008 9:43:12 AM
More...
|
Manhattan Pharmaceuticals, Inc. (MHA) Successfully Completes Pre-IND Meetings for Altoderm and Altolyn
3/6/2008 7:23:59 AM
More...
|
Manhattan Pharmaceuticals, Inc. (MHA) Announces Closing of Joint Venture With Nordic Biotech
2/27/2008 6:22:10 AM
More...
|
Manhattan Pharmaceuticals, Inc. (MHA) to Voluntarily Withdraw Its AMEX Common Stock Listing
2/25/2008 10:18:42 AM
More...
|
|